Tips Round-Up (Premium)
The Sunday Telegraph's James Ashton said although pubco giant JD Wetherspoon's stock boasted the highest valuation in the sector, it still remained investors' "best bet" among boozers.
The shadow chancellor, John McDonnell, has ramped up his attack on the super-rich, describing their wealth as “obscene”, as Labour unveiled research showing one in three billionaires in the UK have made donations to the Tory party. McDonnell is due to take a swipe at the richest people in the country in a speech on Tuesday and will also set out the tax breaks billionaires have benefited from under successive Conservative governments. - Guardian.
The Labour party has pledged to overhaul the public appointments system after one of the government-appointed commissioners who sets the UK minimum wage joined the board of G4S, the security company facing allegations of systematic violations of migrant workers’ human rights. Clare Chapman has served since March 2015 as one of nine commissioners on the government’s Low Pay Commission tasked with setting the national living wage, the legal minimum hourly rate. She was appointed as a G4S director in September.
In his ‘Inside the City’ column for the Sunday Times, John Collingridge wrote about engineering giant Renishaw, starting with its humble beginnings in Sir David McMurtry’s garage in the 1970s, where he invented a tool to measure fuel pipes in the Concorde’s jet engines, while working at Rolls-Royce.
Boris Johnson has announced another election package costing hundreds of millions of pounds for neglected towns, some of which will be spent in marginal constituencies. Concentrating on rundown high streets, the closures of pubs and post offices and the restoration of rail links, the prime minister has claimed that the measures will build upon the £3. 6bn towns fund first announced in July. - Guardian.
In his ‘Inside the City’ column for the Sunday Times, Ben Woods was looking at IT services provider FDM Group, saying it had suffered from the fallout of HSBC’s rationalisation, given the banking giant is one of its biggest clients.
In her ‘Inside the City’ column for the Sunday Times, Sabah Meddings wrote that investors in the City had “all but written off” Shield Therapeutics a year and a half ago, after its treatment for iron-deficient patients had apparently failed a pivotal trial, and so was met with a thumbs-down from the US Food and Drug Administration.